Juba 161 inimeseni on jõudnud selle ettevõtte bränding aga tema tegevusi ei jälgi ükski kasutaja. Keskmiselt on ettevõtet hinnatud 2,3 punktiga aga kommenteeritud ei ole.

Tegevusaruanne 2022

The company had plans to enter new markets, Ukraine and Belarus in 2022 with medical related diagnostic products . This plan faced a major setback after Russian invasion to Ukraine in February, resulting all actions of new plans was seized.

The company will put efforts to reduce depts by capitalizing (selling) its assets and use part of income to pay loans.